Amyris (AMRS) Misses Q3 EPS by 1c

November 2, 2016 4:34 PM EDT
Get Alerts AMRS Hot Sheet
Trade AMRS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Amyris (NASDAQ: AMRS) reported Q3 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $26.5 million versus the consensus estimate of $33.61 million.

“We’re encouraged by the solid momentum in our business, which led to record revenue for the third quarter,” said John Melo, Amyris President & CEO. “We have continued to execute on our business plan to grow our business through collaborations and partnerships, including expansion into the pharmaceutical sector. Our industry leading platform helped us reach a tipping point in demand from some of the leading companies in our target sectors. The combination of the strong growth for our farnesene building block, the new collaborations we are signing and the record number of products in our portfolio that are reaching commercial scale help underpin a very strong fourth quarter and over $200 million of 2017 revenue that we believe is supported by our current business and the remaining collaborations we expect to close in the fourth quarter.”

For earnings history and earnings-related data on Amyris (AMRS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Management Comments

Related Entities

Earnings

Add Your Comment